PMID- 35626136
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 10
DP  - 2022 May 21
TI  - Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma 
      Patients.
LID - 10.3390/cancers14102532 [doi]
LID - 2532
AB  - Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for 
      patients initiating a first highly haematotoxic treatment for Hodgkin or 
      non-Hodgkin lymphoma. Patient follow-up is based on consultation with a 
      pharmacist and planed phone calls by nurses supervised by a clinical 
      haematologist. Our objective was to assess effectiveness and cost of the UMACOACH 
      Lymphoma Program (ULP) and to investigate patient satisfaction and quality of 
      life (QoL). Methods: This French monocentric case-control study included all 
      patients enrolled in the ULP over a one-year period (cases) matched with 
      retrospective patients receiving usual care (controls). Numbers of adverse events 
      (AEs), re-hospitalisations, average relative dose intensity (ARDI), treatment 
      response and survival were compared between the two groups. Among cases, patient 
      satisfaction and QoL using the EORTC-QLQC30 questionnaire before and after 
      treatment were evaluated. Results: Seventy-eight cases were matched to 78 
      controls. Twenty-six percent grade 3-4 AEs were observed in cases versus 38% in 
      controls (p = 0.001). There were 76 and 88 re-hospitalisations in the case and 
      control groups, respectively (p = 0.217). ARDI > 85% was observed in 92% and 82% 
      of cases and controls, respectively (p = 0.138). No differences were observed in 
      terms of treatment responses and survival. Estimated cost savings were of EUR 
      81,782 in favour of the case group. An improvement of 5.1 points was observed in 
      the total QoL score before and after treatment in cases. Conclusions: A 
      nurse-pharmacist-haematologist collaboration seems to be promising to reduce 
      grade 3-4 AEs in HL and NHL patients receiving highly haematotoxic chemotherapy 
      regimens. Cost savings from hospitalisation being avoided were also shown.
FAU - Devaux, Madeline
AU  - Devaux M
AD  - Department of Pharmacy, University Hospital, F-21000 Dijon, France.
FAU - Boulin, Mathieu
AU  - Boulin M
AUID- ORCID: 0000-0002-3504-7250
AD  - Department of Pharmacy, University Hospital and EPICAD LNC UMR1231, University of 
      Burgundy & Franche Comte, F-21000 Dijon, France.
FAU - Mounier, Morgane
AU  - Mounier M
AD  - Registre des Hemopathies Malignes de Cote d'Or, Dijon-Bourgogne University 
      Hospital, F-21000 Dijon, France.
AD  - INSERM, U1231, University of Burgundy & Franche Comte, UMR 1231, F-21000 Dijon, 
      France.
FAU - Caillot, Denis
AU  - Caillot D
AD  - Department of Clinical Hematology, University Hospital INSERM UMR1231 and 
      SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, France.
FAU - Ahwij, Nuri
AU  - Ahwij N
AD  - Department of Clinical Hematology, University Hospital, F-21000 Dijon, France.
FAU - Herbin, Adelie
AU  - Herbin A
AD  - Department of Clinical Hematology, University Hospital, F-21000 Dijon, France.
FAU - Bastie, Jean Noel
AU  - Bastie JN
AD  - Department of Clinical Hematology, University Hospital, F-21000 Dijon, France.
FAU - Favennec, Camille
AU  - Favennec C
AD  - Department of Clinical Hematology, University Hospital, F-21000 Dijon, France.
FAU - Robert, Philippine
AU  - Robert P
AD  - Department of Clinical Hematology, University Hospital, F-21000 Dijon, France.
FAU - Pistre, Pauline
AU  - Pistre P
AD  - Department of Pharmacy, University Hospital, F-21000 Dijon, France.
FAU - Bost, Stephanie
AU  - Bost S
AD  - Department of Pharmacy, University Hospital, F-21000 Dijon, France.
FAU - Amiot, Pauline
AU  - Amiot P
AD  - Department of Clinical Hematology, University Hospital, F-21000 Dijon, France.
FAU - Jacquesson, Laurence
AU  - Jacquesson L
AD  - Department of Clinical Hematology, University Hospital, F-21000 Dijon, France.
FAU - Casasnovas, Olivier
AU  - Casasnovas O
AUID- ORCID: 0000-0002-1156-8983
AD  - Department of Clinical Hematology, University Hospital INSERM UMR1231 and 
      SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, France.
FAU - Rossi, Cedric
AU  - Rossi C
AUID- ORCID: 0000-0003-3717-7961
AD  - Department of Clinical Hematology, University Hospital and SAPHIIR-UMR 1231, 
      University of Burgundy & Franche Comte, F-21000 Dijon, France.
FAU - Gueneau, Pauline
AU  - Gueneau P
AD  - Department of Pharmacy, University Hospital, F-21000 Dijon, France.
LA  - eng
PT  - Journal Article
DEP - 20220521
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9139274
OTO - NOTNLM
OT  - follow-up
OT  - haematotoxicity
OT  - immunochemotherapy
OT  - lymphoma
OT  - nurse
OT  - pharmacist
OT  - quality of life
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/29 06:00
MHDA- 2022/05/29 06:01
PMCR- 2022/05/21
CRDT- 2022/05/28 01:09
PHST- 2022/04/24 00:00 [received]
PHST- 2022/05/12 00:00 [revised]
PHST- 2022/05/18 00:00 [accepted]
PHST- 2022/05/28 01:09 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/05/29 06:01 [medline]
PHST- 2022/05/21 00:00 [pmc-release]
AID - cancers14102532 [pii]
AID - cancers-14-02532 [pii]
AID - 10.3390/cancers14102532 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 May 21;14(10):2532. doi: 10.3390/cancers14102532.